Inactive Instrument

Vital Therapies Inc Nasdaq

Equities

US92847R1041

Biotechnology & Medical Research

Vital Therapies to Present at the Jefferies 2018 Global Healthcare Conference

June 07, 2018 at 08:01 am EDT

SAN DIEGO, June 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that Russell J. Cox, Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference in New York City at 8:30 a.m. ET on Friday, June 8.

A live webcast of the presentation will be available on the Investor Relations page of the Company's website at: http://ir.vitaltherapies.com/. An archive of the presentation will be available for replay following the conference.

About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company’s ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
akildani@vitaltherapies.com

Latest news about Vital Therapies Inc

Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	Mar. 21	MT
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	Feb. 23	MT
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	Jan. 05	MT
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	Jan. 05	MT
Top Premarket Gainers	Jan. 05	MT
Immunic Files $250 Million Mixed-Securities Shelf Registration	Nov. 22	MT
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	Nov. 21	MT
Transcript : Immunic, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	Nov. 02	CI
Immunic Says Early-Stage Trial Shows 'Positive Effects' of Celiac Disease Drug Over Placebo	23-10-16	MT
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	23-10-15	CI
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	23-10-10	MT
Transcript : Immunic, Inc. - Special Call	23-10-10
Top Premarket Gainers	23-10-10	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Immunic Says Phase 2 Trial Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Soar Premarket	23-10-10	MT
Health Care Up on Deal Activity -- Health Care Roundup	23-10-09	DJ
Immunic Says Phase 2 Trial Further Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Rise After Hours	23-10-09	MT
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis	23-10-09	CI
Immunic Completes Enrollment for Calliper Trial Phase 2	23-08-17	MT

Chart Vital Therapies Inc

Duration

Period

More charts

Company Profile

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-04-16 - Noble Capital Markets Emerging Growth Virtual Health Care Equity Conference

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	102B
REGENERON PHARMACEUTICALS, INC.	+2.31%	97.22B
ARGENX SE	+4.22%	22.27B
BIONTECH SE	-16.72%	20.84B
GENMAB A/S	-4.50%	19.19B
WUXI APPTEC CO., LTD.	-41.75%	16.76B
BEIGENE, LTD.	-23.26%	14.76B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.54B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.53B

Bio Therapeutic Drugs